Valocorphytun (Tablets) Instructions for Use
Marketing Authorization Holder
Krewel Meuselbach, LLC (Russia)
Manufactured By
PharmVILAR NPO, LLC (Russia)
ATC Code
N05CM (Other hypnotic and sedative drugs)
Active Substances
Extractum rhizomatum cum radicibus Valerianae officinalis (Grouping name)
Peppermint (USAN)
Melissa (DAB)
Dosage Form
| Valocorphytun | Film-coated tablets 35 mg+17.5 mg+17.5 mg: 20, 40, 50, 60, or 80 pcs. |
Dosage Form, Packaging, and Composition
Film-coated tablets light green in color, round, biconvex.
| 1 tab. | |
| Premix Phyto | 71.4 mg |
| (consisting of dry extract of Valeriana officinalis rhizomes with roots – 35 mg, dry extract of Melissa officinalis leaves – 17.5 mg, dry extract of Mentha piperita leaves – 17.5 mg, precipitated silicon dioxide – 1.4 mg) | |
Excipients : lactose monohydrate, potato starch, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate.
Shell composition povidone K-17, sucrose, colloidal silicon dioxide, magnesium carbonate, “tarragon” dye, titanium dioxide, talc, wax (capol).
10 pcs. – contour cell packs (2) – cardboard packs.
10 pcs. – contour cell packs (4) – cardboard packs.
10 pcs. – contour cell packs (6) – cardboard packs.
10 pcs. – contour cell packs (8) – cardboard packs.
50 pcs. – polymer jars (1) – cardboard packs.
Clinical-Pharmacological Group
Sedative herbal preparation
Pharmacotherapeutic Group
Herbal sedative
Pharmacological Action
A combined herbal medicine with sedative and spasmolytic effects.
Extract of valerian rhizomes with roots has a sedative effect.
Extract of lemon balm leaves has sedative and spasmolytic effects.
Extract of peppermint leaves has spasmolytic and moderate sedative effects.
Indications
Increased nervous excitability; insomnia; irritability.
ICD codes
| ICD-10 code | Indication |
| F48.0 | Neurasthenia |
| F48.9 | Unspecified neurotic disorder |
| F51.0 | Nonorganic insomnia |
| R45.0 | Nervousness |
| R45.4 | Irritability and anger |
| ICD-11 code | Indication |
| 6A8Z | Affective disorders, unspecified |
| 6B6Z | Dissociative disorders, unspecified |
| 7A00 | Chronic insomnia |
| 7A01 | Acute insomnia |
| 7A0Z | Insomnia disorders, unspecified |
| MB24.3 | Anxiety |
| MB24.C | Irritability |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Administer the drug orally.
Take a single dose of one to two tablets.
Adhere to a frequency of two to three times daily.
Ingest the last dose 30 minutes to one hour before bedtime to facilitate sleep onset.
Do not exceed the maximum daily dose of six tablets.
Swallow the tablet whole with a sufficient amount of water.
Do not use the drug continuously for more than 1.5 to 2 months without consulting a physician.
Discontinue use if no therapeutic benefit is observed after a treatment period of 2-4 weeks.
Be aware that withdrawal syndrome does not develop upon cessation of therapy.
For patients with GERD, monitor for potential worsening of symptoms.
Exercise caution when engaging in activities requiring increased concentration and psychomotor speed, such as driving or operating machinery.
Adverse Reactions
Allergic reactions possible – hyperemia, skin rash, peripheral edema, allergic dermatitis), bronchospasm.
From the digestive system with prolonged use, constipation is possible.
Contraindications
Arterial hypotension; cholangitis, cholelithiasis and other diseases of the biliary tract; pregnancy, breastfeeding period; children under 12 years of age; hypersensitivity to the components of the drug.
With caution GERD.
Use in Pregnancy and Lactation
Use during pregnancy and lactation (breastfeeding) is contraindicated.
Pediatric Use
The use of the drug in children under 12 years of age is contraindicated.
Special Precautions
In patients with GERD, a worsening of symptoms is possible.
If symptoms persist or worsen during the use of the drug, the patient should consult a doctor.
The drug should not be used continuously for more than 1.5-2 months.
Effect on the ability to drive vehicles and mechanisms
During treatment, patients should exercise caution when engaging in potentially hazardous activities that require increased concentration and speed of psychomotor reactions (driving vehicles, working with moving mechanisms, work of a dispatcher, operator).
Drug Interactions
With simultaneous use of the drug with other drugs that depress the central nervous system (including hypnotics, centrally acting antihypertensive drugs, analgesics), an enhancement of the effect on the central nervous system is possible (dose adjustment may be required).
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Over-the-Counter
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical Disclaimer
OKI, sachets 80mg 2g, 12pcs
Picamilon pills 50mg, 60pcs
Ingavirin capsules 90mg, 10pcs
Belosalic, ointment, 30g
Mildronate capsules 500mg, 90pcs
Phenibut-Vertex pills 250mg, 20pcs
Daivobet, ointment, 30g
Cerebrolysin, solution for injection 2ml ampoules 10pcs
Nootropil pills 800mg, 30pcs
Kagocel pills 12mg, 30pcs
Cavinton Comfort, dispersible pills 10mg 90pcs
Cortexin, 10mg, 5ml, 10pcs
Belosalic, lotion solution for external use spray 100ml
Arbidol, capsules 100mg, 40pcs
Fenotropil pills 100mg, 60pcs
Actovegin pills 200mg, 50pcs
Noopept, pills 10mg, 50pcs 